ArticleBrain & spine2026
Pre-existing statin use and recurrence in relation to hematoma architecture of chronic subdural hematomas - A propensity score-matched analysis.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic Subdural Hematoma: Pathophysiology, Diagnosis, and the Emerging Role of Middle Meningeal Artery Embolization.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic subdural hematoma (cSDH) affects increasing patient numbers annually, with postoperative recurrence rates of 5-33%. While atorvastatin shows efficacy as primary conservative treatment, the prognostic value of pre-existing statin use in surgical candidates remains unclear. Research question: This study examined associations between pre-existing statin therapy, hematoma architecture on computed tomography, and postoperative recurrence risk. Material and methods: This retrospective cohort study analyzed 564 consecutive patients surgically treated for cSDH at a tertiary center (2015-2023). Pre-existing statin use was documented and hematoma architecture classified into homogeneous, organized, sedimented, and subacute subtypes. The primary outcome was recurrence requiring reoperation. Multivariable logistic regression with hierarchical adjustment evaluated associations between statin use and recurrence, adjusting for demographics, comorbidities, medications, and hematoma characteristics. Interaction analyses tested whether statin effects varied by architecture. Propensity score matching (1:1, n = 252) reduced confounding. Results: Statin use was documented in 150 patients (26.6%). Recurrence occurred in 170 patients (30.1%): 32.9% in non-users versus 22.7% in users. Unadjusted analysis suggested protection (OR 0.599, p = 0.021), but this attenuated after adjusting for cardiovascular comorbidities (OR 0.649, p = 0.076) and became non-significant after full adjustment (OR 0.664, p = 0.109). Propensity matching corroborated findings (OR 0.736, p = 0.269). Hematoma architecture was the dominant predictor: organized hematomas showed 70% lower recurrence risk (OR 0.303, p < 0.001). No differential statin effects across subtypes were observed (p = 0.668). Discussion and conclusion: Pre-existing statin therapy shows no independent association with postoperative recurrence after adjusting for confounders and hematoma architecture. Prospective investigation of post-surgical statin initiation is warranted. Trial registration: The study was registered with the German Clinical Trials Register (DRKS00025280).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.